nodes	percent_of_prediction	percent_of_DWPC	metapath
Olanzapine—DRD5—attention deficit hyperactivity disorder	0.161	0.212	CbGaD
Olanzapine—ADRA2C—attention deficit hyperactivity disorder	0.151	0.2	CbGaD
Olanzapine—DRD4—attention deficit hyperactivity disorder	0.0822	0.108	CbGaD
Olanzapine—HTR1B—attention deficit hyperactivity disorder	0.073	0.0961	CbGaD
Olanzapine—DRD3—attention deficit hyperactivity disorder	0.0709	0.0933	CbGaD
Olanzapine—DRD1—attention deficit hyperactivity disorder	0.0696	0.0916	CbGaD
Olanzapine—ADRA2A—attention deficit hyperactivity disorder	0.0646	0.0851	CbGaD
Olanzapine—DRD2—attention deficit hyperactivity disorder	0.049	0.0646	CbGaD
Olanzapine—HTR2A—attention deficit hyperactivity disorder	0.0379	0.0499	CbGaD
Olanzapine—HTR7—locus ceruleus—attention deficit hyperactivity disorder	0.00341	0.051	CbGeAlD
Olanzapine—HTR5A—forebrain—attention deficit hyperactivity disorder	0.00271	0.0406	CbGeAlD
Olanzapine—ORM1—saliva—attention deficit hyperactivity disorder	0.00245	0.0366	CbGeAlD
Olanzapine—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00212	0.0318	CbGeAlD
Olanzapine—HTR7—autonomic nervous system—attention deficit hyperactivity disorder	0.00181	0.0271	CbGeAlD
Olanzapine—HTR5A—nervous system—attention deficit hyperactivity disorder	0.00147	0.022	CbGeAlD
Olanzapine—HTR5A—central nervous system—attention deficit hyperactivity disorder	0.00142	0.0212	CbGeAlD
Olanzapine—HTR1E—forebrain—attention deficit hyperactivity disorder	0.00116	0.0173	CbGeAlD
Olanzapine—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00113	0.0169	CbGeAlD
Olanzapine—HTR5A—brain—attention deficit hyperactivity disorder	0.00112	0.0168	CbGeAlD
Olanzapine—HTR6—forebrain—attention deficit hyperactivity disorder	0.000907	0.0136	CbGeAlD
Olanzapine—DRD5—forebrain—attention deficit hyperactivity disorder	0.000883	0.0132	CbGeAlD
Olanzapine—HRH2—cardiovascular system—attention deficit hyperactivity disorder	0.000701	0.0105	CbGeAlD
Olanzapine—H1F0—forebrain—attention deficit hyperactivity disorder	0.000683	0.0102	CbGeAlD
Olanzapine—DRD1—forebrain—attention deficit hyperactivity disorder	0.000675	0.0101	CbGeAlD
Olanzapine—HTR3A—forebrain—attention deficit hyperactivity disorder	0.000652	0.00976	CbGeAlD
Olanzapine—HTR1E—nervous system—attention deficit hyperactivity disorder	0.000628	0.0094	CbGeAlD
Olanzapine—HTR1E—central nervous system—attention deficit hyperactivity disorder	0.000604	0.00905	CbGeAlD
Olanzapine—H1F0—cardiovascular system—attention deficit hyperactivity disorder	0.000578	0.00866	CbGeAlD
Olanzapine—DRD4—brain—attention deficit hyperactivity disorder	0.000556	0.00833	CbGeAlD
Olanzapine—CHRM4—nervous system—attention deficit hyperactivity disorder	0.00055	0.00824	CbGeAlD
Olanzapine—HTR1B—forebrain—attention deficit hyperactivity disorder	0.000547	0.00819	CbGeAlD
Olanzapine—CHRM2—forebrain—attention deficit hyperactivity disorder	0.000544	0.00815	CbGeAlD
Olanzapine—CHRM4—central nervous system—attention deficit hyperactivity disorder	0.00053	0.00794	CbGeAlD
Olanzapine—HTR1D—forebrain—attention deficit hyperactivity disorder	0.000529	0.00793	CbGeAlD
Olanzapine—HTR2C—forebrain—attention deficit hyperactivity disorder	0.000524	0.00785	CbGeAlD
Olanzapine—DRD3—nervous system—attention deficit hyperactivity disorder	0.000512	0.00766	CbGeAlD
Olanzapine—FMO3—nervous system—attention deficit hyperactivity disorder	0.000506	0.00758	CbGeAlD
Olanzapine—CHRM1—forebrain—attention deficit hyperactivity disorder	0.000495	0.00742	CbGeAlD
Olanzapine—DRD3—central nervous system—attention deficit hyperactivity disorder	0.000493	0.00738	CbGeAlD
Olanzapine—HTR6—nervous system—attention deficit hyperactivity disorder	0.000492	0.00738	CbGeAlD
Olanzapine—HTR2B—forebrain—attention deficit hyperactivity disorder	0.000492	0.00738	CbGeAlD
Olanzapine—FMO3—central nervous system—attention deficit hyperactivity disorder	0.000487	0.0073	CbGeAlD
Olanzapine—HTR1E—brain—attention deficit hyperactivity disorder	0.00048	0.00719	CbGeAlD
Olanzapine—DRD5—nervous system—attention deficit hyperactivity disorder	0.000479	0.00718	CbGeAlD
Olanzapine—HTR6—central nervous system—attention deficit hyperactivity disorder	0.000474	0.0071	CbGeAlD
Olanzapine—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.000462	0.00693	CbGeAlD
Olanzapine—DRD5—central nervous system—attention deficit hyperactivity disorder	0.000462	0.00691	CbGeAlD
Olanzapine—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.00046	0.00689	CbGeAlD
Olanzapine—H1F0—midbrain—attention deficit hyperactivity disorder	0.000451	0.00676	CbGeAlD
Olanzapine—HRH2—nervous system—attention deficit hyperactivity disorder	0.00045	0.00674	CbGeAlD
Olanzapine—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.000448	0.00671	CbGeAlD
Olanzapine—DRD1—midbrain—attention deficit hyperactivity disorder	0.000446	0.00668	CbGeAlD
Olanzapine—CHRM3—forebrain—attention deficit hyperactivity disorder	0.000443	0.00664	CbGeAlD
Olanzapine—HTR1A—forebrain—attention deficit hyperactivity disorder	0.000441	0.00661	CbGeAlD
Olanzapine—HRH2—central nervous system—attention deficit hyperactivity disorder	0.000433	0.00649	CbGeAlD
Olanzapine—CHRM5—nervous system—attention deficit hyperactivity disorder	0.00043	0.00644	CbGeAlD
Olanzapine—HTR7—forebrain—attention deficit hyperactivity disorder	0.000422	0.00632	CbGeAlD
Olanzapine—CHRM4—brain—attention deficit hyperactivity disorder	0.000421	0.0063	CbGeAlD
Olanzapine—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.000419	0.00627	CbGeAlD
Olanzapine—HTR2B—cardiovascular system—attention deficit hyperactivity disorder	0.000416	0.00624	CbGeAlD
Olanzapine—CHRM5—central nervous system—attention deficit hyperactivity disorder	0.000414	0.0062	CbGeAlD
Olanzapine—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000407	0.00609	CbGeAlD
Olanzapine—DRD2—forebrain—attention deficit hyperactivity disorder	0.000399	0.00597	CbGeAlD
Olanzapine—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000393	0.00589	CbGeAlD
Olanzapine—DRD3—brain—attention deficit hyperactivity disorder	0.000391	0.00586	CbGeAlD
Olanzapine—FMO3—brain—attention deficit hyperactivity disorder	0.000387	0.00579	CbGeAlD
Olanzapine—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000378	0.00567	CbGeAlD
Olanzapine—HTR6—brain—attention deficit hyperactivity disorder	0.000376	0.00564	CbGeAlD
Olanzapine—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.000373	0.00559	CbGeAlD
Olanzapine—H1F0—nervous system—attention deficit hyperactivity disorder	0.000371	0.00556	CbGeAlD
Olanzapine—DRD5—brain—attention deficit hyperactivity disorder	0.000366	0.00549	CbGeAlD
Olanzapine—DRD1—nervous system—attention deficit hyperactivity disorder	0.000366	0.00549	CbGeAlD
Olanzapine—HTR1B—midbrain—attention deficit hyperactivity disorder	0.000361	0.00541	CbGeAlD
Olanzapine—H1F0—central nervous system—attention deficit hyperactivity disorder	0.000357	0.00535	CbGeAlD
Olanzapine—HTR7—cardiovascular system—attention deficit hyperactivity disorder	0.000357	0.00534	CbGeAlD
Olanzapine—HTR3A—nervous system—attention deficit hyperactivity disorder	0.000354	0.0053	CbGeAlD
Olanzapine—DRD1—central nervous system—attention deficit hyperactivity disorder	0.000353	0.00528	CbGeAlD
Olanzapine—HTR1D—midbrain—attention deficit hyperactivity disorder	0.00035	0.00524	CbGeAlD
Olanzapine—H1F0—cerebellum—attention deficit hyperactivity disorder	0.000349	0.00523	CbGeAlD
Olanzapine—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000346	0.00519	CbGeAlD
Olanzapine—HRH2—brain—attention deficit hyperactivity disorder	0.000344	0.00516	CbGeAlD
Olanzapine—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000344	0.00515	CbGeAlD
Olanzapine—HTR3A—central nervous system—attention deficit hyperactivity disorder	0.000341	0.0051	CbGeAlD
Olanzapine—Loxapine—DRD5—attention deficit hyperactivity disorder	0.000332	0.054	CrCbGaD
Olanzapine—CHRM5—brain—attention deficit hyperactivity disorder	0.000329	0.00493	CbGeAlD
Olanzapine—Quetiapine—DRD5—attention deficit hyperactivity disorder	0.000324	0.0527	CrCbGaD
Olanzapine—ORM1—nervous system—attention deficit hyperactivity disorder	0.000317	0.00474	CbGeAlD
Olanzapine—HRH1—forebrain—attention deficit hyperactivity disorder	0.000315	0.00472	CbGeAlD
Olanzapine—Loxapine—ADRA2C—attention deficit hyperactivity disorder	0.000313	0.0509	CrCbGaD
Olanzapine—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000309	0.00463	CbGeAlD
Olanzapine—Quetiapine—ADRA2C—attention deficit hyperactivity disorder	0.000306	0.0497	CrCbGaD
Olanzapine—ORM1—central nervous system—attention deficit hyperactivity disorder	0.000305	0.00457	CbGeAlD
Olanzapine—ADRA1B—brain—attention deficit hyperactivity disorder	0.0003	0.0045	CbGeAlD
Olanzapine—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000297	0.00445	CbGeAlD
Olanzapine—CHRM2—nervous system—attention deficit hyperactivity disorder	0.000295	0.00442	CbGeAlD
Olanzapine—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000291	0.00436	CbGeAlD
Olanzapine—Clozapine—HRH3—attention deficit hyperactivity disorder	0.000288	0.0468	CrCbGaD
Olanzapine—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000287	0.0043	CbGeAlD
Olanzapine—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000286	0.00428	CbGeAlD
Olanzapine—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000285	0.00426	CbGeAlD
Olanzapine—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.000284	0.00426	CbGeAlD
Olanzapine—H1F0—brain—attention deficit hyperactivity disorder	0.000284	0.00425	CbGeAlD
Olanzapine—DRD1—brain—attention deficit hyperactivity disorder	0.00028	0.00419	CbGeAlD
Olanzapine—HTR7—midbrain—attention deficit hyperactivity disorder	0.000278	0.00417	CbGeAlD
Olanzapine—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000277	0.00414	CbGeAlD
Olanzapine—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000274	0.0041	CbGeAlD
Olanzapine—HTR3A—brain—attention deficit hyperactivity disorder	0.00027	0.00405	CbGeAlD
Olanzapine—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.00027	0.00404	CbGeAlD
Olanzapine—CHRM1—nervous system—attention deficit hyperactivity disorder	0.000269	0.00403	CbGeAlD
Olanzapine—HTR2B—nervous system—attention deficit hyperactivity disorder	0.000267	0.004	CbGeAlD
Olanzapine—DRD2—midbrain—attention deficit hyperactivity disorder	0.000263	0.00394	CbGeAlD
Olanzapine—Clozapine—ADRA2C—attention deficit hyperactivity disorder	0.000263	0.0427	CrCbGaD
Olanzapine—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000263	0.00394	CbGeAlD
Olanzapine—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.000259	0.00388	CbGeAlD
Olanzapine—HTR2B—central nervous system—attention deficit hyperactivity disorder	0.000257	0.00386	CbGeAlD
Olanzapine—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000256	0.00383	CbGeAlD
Olanzapine—CHRM3—nervous system—attention deficit hyperactivity disorder	0.00024	0.0036	CbGeAlD
Olanzapine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00024	0.00359	CbGeAlD
Olanzapine—HTR1A—nervous system—attention deficit hyperactivity disorder	0.00024	0.00359	CbGeAlD
Olanzapine—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.000232	0.00347	CbGeAlD
Olanzapine—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000231	0.00345	CbGeAlD
Olanzapine—HTR7—nervous system—attention deficit hyperactivity disorder	0.000229	0.00343	CbGeAlD
Olanzapine—HTR1B—brain—attention deficit hyperactivity disorder	0.000227	0.0034	CbGeAlD
Olanzapine—CHRM2—brain—attention deficit hyperactivity disorder	0.000226	0.00338	CbGeAlD
Olanzapine—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.000225	0.00338	CbGeAlD
Olanzapine—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000222	0.00333	CbGeAlD
Olanzapine—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000221	0.00331	CbGeAlD
Olanzapine—HTR7—central nervous system—attention deficit hyperactivity disorder	0.00022	0.0033	CbGeAlD
Olanzapine—HTR1D—brain—attention deficit hyperactivity disorder	0.00022	0.00329	CbGeAlD
Olanzapine—Amoxapine—DRD4—attention deficit hyperactivity disorder	0.000218	0.0353	CrCbGaD
Olanzapine—HTR2C—brain—attention deficit hyperactivity disorder	0.000218	0.00326	CbGeAlD
Olanzapine—DRD2—nervous system—attention deficit hyperactivity disorder	0.000216	0.00324	CbGeAlD
Olanzapine—HTR7—cerebellum—attention deficit hyperactivity disorder	0.000215	0.00323	CbGeAlD
Olanzapine—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000213	0.00318	CbGeAlD
Olanzapine—ALB—brain—attention deficit hyperactivity disorder	0.000212	0.00318	CbGeAlD
Olanzapine—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.00021	0.00315	CbGeAlD
Olanzapine—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000208	0.00312	CbGeAlD
Olanzapine—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000208	0.00311	CbGeAlD
Olanzapine—CHRM1—brain—attention deficit hyperactivity disorder	0.000205	0.00308	CbGeAlD
Olanzapine—HTR2B—brain—attention deficit hyperactivity disorder	0.000204	0.00306	CbGeAlD
Olanzapine—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000204	0.00306	CbGeAlD
Olanzapine—DRD2—cerebellum—attention deficit hyperactivity disorder	0.000204	0.00305	CbGeAlD
Olanzapine—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000203	0.00303	CbGeAlD
Olanzapine—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.000198	0.00297	CbGeAlD
Olanzapine—Amoxapine—HTR1B—attention deficit hyperactivity disorder	0.000193	0.0314	CrCbGaD
Olanzapine—Amoxapine—DRD3—attention deficit hyperactivity disorder	0.000188	0.0305	CrCbGaD
Olanzapine—Amoxapine—DRD1—attention deficit hyperactivity disorder	0.000184	0.0299	CrCbGaD
Olanzapine—CHRM3—brain—attention deficit hyperactivity disorder	0.000184	0.00275	CbGeAlD
Olanzapine—HTR1A—brain—attention deficit hyperactivity disorder	0.000183	0.00274	CbGeAlD
Olanzapine—HTR7—brain—attention deficit hyperactivity disorder	0.000175	0.00262	CbGeAlD
Olanzapine—Amoxapine—SLC6A3—attention deficit hyperactivity disorder	0.000175	0.0284	CrCbGaD
Olanzapine—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000174	0.0026	CbGeAlD
Olanzapine—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000172	0.00258	CbGeAlD
Olanzapine—Amoxapine—ADRA2A—attention deficit hyperactivity disorder	0.000171	0.0278	CrCbGaD
Olanzapine—HRH1—nervous system—attention deficit hyperactivity disorder	0.000171	0.00256	CbGeAlD
Olanzapine—Loxapine—DRD4—attention deficit hyperactivity disorder	0.00017	0.0276	CrCbGaD
Olanzapine—ADRA1A—brain—attention deficit hyperactivity disorder	0.000169	0.00253	CbGeAlD
Olanzapine—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000168	0.00252	CbGeAlD
Olanzapine—Quetiapine—DRD4—attention deficit hyperactivity disorder	0.000166	0.0269	CrCbGaD
Olanzapine—DRD2—brain—attention deficit hyperactivity disorder	0.000165	0.00248	CbGeAlD
Olanzapine—HRH1—central nervous system—attention deficit hyperactivity disorder	0.000165	0.00247	CbGeAlD
Olanzapine—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000162	0.00242	CbGeAlD
Olanzapine—ADRA2C—brain—attention deficit hyperactivity disorder	0.000161	0.00241	CbGeAlD
Olanzapine—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000158	0.00237	CbGeAlD
Olanzapine—Loxapine—HTR1B—attention deficit hyperactivity disorder	0.000151	0.0245	CrCbGaD
Olanzapine—Quetiapine—HTR1B—attention deficit hyperactivity disorder	0.000147	0.0239	CrCbGaD
Olanzapine—Loxapine—DRD3—attention deficit hyperactivity disorder	0.000146	0.0238	CrCbGaD
Olanzapine—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000146	0.00218	CbGeAlD
Olanzapine—Loxapine—DRD1—attention deficit hyperactivity disorder	0.000144	0.0234	CrCbGaD
Olanzapine—Quetiapine—DRD3—attention deficit hyperactivity disorder	0.000143	0.0232	CrCbGaD
Olanzapine—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000143	0.00214	CbGeAlD
Olanzapine—Clozapine—DRD4—attention deficit hyperactivity disorder	0.000143	0.0232	CrCbGaD
Olanzapine—Quetiapine—DRD1—attention deficit hyperactivity disorder	0.00014	0.0228	CrCbGaD
Olanzapine—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000137	0.00206	CbGeAlD
Olanzapine—Loxapine—SLC6A3—attention deficit hyperactivity disorder	0.000136	0.0221	CrCbGaD
Olanzapine—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000134	0.00201	CbGeAlD
Olanzapine—Loxapine—ADRA2A—attention deficit hyperactivity disorder	0.000134	0.0217	CrCbGaD
Olanzapine—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000132	0.00198	CbGeAlD
Olanzapine—HRH1—brain—attention deficit hyperactivity disorder	0.000131	0.00196	CbGeAlD
Olanzapine—Amoxapine—SLC6A4—attention deficit hyperactivity disorder	0.000131	0.0212	CrCbGaD
Olanzapine—Quetiapine—ADRA2A—attention deficit hyperactivity disorder	0.00013	0.0212	CrCbGaD
Olanzapine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.00013	0.00195	CbGeAlD
Olanzapine—Amoxapine—DRD2—attention deficit hyperactivity disorder	0.00013	0.0211	CrCbGaD
Olanzapine—ADRA2A—brain—attention deficit hyperactivity disorder	0.000128	0.00192	CbGeAlD
Olanzapine—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000127	0.00191	CbGeAlD
Olanzapine—Clozapine—HTR1B—attention deficit hyperactivity disorder	0.000127	0.0206	CrCbGaD
Olanzapine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000125	0.00188	CbGeAlD
Olanzapine—Clozapine—DRD3—attention deficit hyperactivity disorder	0.000123	0.02	CrCbGaD
Olanzapine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000122	0.00183	CbGeAlD
Olanzapine—Clozapine—DRD1—attention deficit hyperactivity disorder	0.000121	0.0196	CrCbGaD
Olanzapine—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000114	0.0017	CbGeAlD
Olanzapine—Clozapine—ADRA2A—attention deficit hyperactivity disorder	0.000112	0.0182	CrCbGaD
Olanzapine—HTR2A—brain—attention deficit hyperactivity disorder	0.000109	0.00163	CbGeAlD
Olanzapine—Loxapine—SLC6A4—attention deficit hyperactivity disorder	0.000102	0.0166	CrCbGaD
Olanzapine—Loxapine—DRD2—attention deficit hyperactivity disorder	0.000101	0.0165	CrCbGaD
Olanzapine—Amoxapine—HTR2A—attention deficit hyperactivity disorder	0.0001	0.0163	CrCbGaD
Olanzapine—CYP2D6—brain—attention deficit hyperactivity disorder	9.94e-05	0.00149	CbGeAlD
Olanzapine—Quetiapine—DRD2—attention deficit hyperactivity disorder	9.9e-05	0.0161	CrCbGaD
Olanzapine—ABCB1—nervous system—attention deficit hyperactivity disorder	9.35e-05	0.0014	CbGeAlD
Olanzapine—ABCB1—central nervous system—attention deficit hyperactivity disorder	9.01e-05	0.00135	CbGeAlD
Olanzapine—ABCB1—cerebellum—attention deficit hyperactivity disorder	8.8e-05	0.00132	CbGeAlD
Olanzapine—Clozapine—DRD2—attention deficit hyperactivity disorder	8.51e-05	0.0138	CrCbGaD
Olanzapine—Loxapine—HTR2A—attention deficit hyperactivity disorder	7.83e-05	0.0127	CrCbGaD
Olanzapine—Quetiapine—HTR2A—attention deficit hyperactivity disorder	7.65e-05	0.0124	CrCbGaD
Olanzapine—ABCB1—brain—attention deficit hyperactivity disorder	7.15e-05	0.00107	CbGeAlD
Olanzapine—Clozapine—HTR2A—attention deficit hyperactivity disorder	6.58e-05	0.0107	CrCbGaD
Olanzapine—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.13e-06	3.06e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.12e-06	3.05e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.09e-06	3.03e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.09e-06	3.03e-05	CbGpPWpGaD
Olanzapine—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.07e-06	3.02e-05	CbGpPWpGaD
Olanzapine—HRH2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.03e-06	3e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.03e-06	3e-05	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.03e-06	3e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.02e-06	2.99e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.01e-06	2.98e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.01e-06	2.98e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.01e-06	2.98e-05	CbGpPWpGaD
Olanzapine—DRD5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5e-06	2.98e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.98e-06	2.97e-05	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.98e-06	2.97e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.95e-06	2.95e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.94e-06	2.94e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.92e-06	2.93e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.91e-06	2.92e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.86e-06	2.9e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.85e-06	2.89e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.85e-06	2.89e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.84e-06	2.88e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.82e-06	2.87e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.81e-06	2.87e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.77e-06	2.84e-05	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.77e-06	2.84e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.74e-06	2.83e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.68e-06	2.79e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.68e-06	2.79e-05	CbGpPWpGaD
Olanzapine—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.68e-06	2.79e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.67e-06	2.78e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.66e-06	2.77e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.63e-06	2.76e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	4.62e-06	2.76e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.61e-06	2.74e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.59e-06	2.74e-05	CbGpPWpGaD
Olanzapine—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.59e-06	2.74e-05	CbGpPWpGaD
Olanzapine—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.58e-06	2.73e-05	CbGpPWpGaD
Olanzapine—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.56e-06	2.72e-05	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.54e-06	2.71e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.54e-06	2.7e-05	CbGpPWpGaD
Olanzapine—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.52e-06	2.69e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.51e-06	2.69e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.51e-06	2.68e-05	CbGpPWpGaD
Olanzapine—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.5e-06	2.68e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.5e-06	2.68e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.49e-06	2.67e-05	CbGpPWpGaD
Olanzapine—FMO3—Metabolism—EP300—attention deficit hyperactivity disorder	4.46e-06	2.65e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.44e-06	2.64e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.43e-06	2.64e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.41e-06	2.63e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.4e-06	2.62e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.38e-06	2.61e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.38e-06	2.61e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.38e-06	2.61e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.36e-06	2.6e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.36e-06	2.6e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.33e-06	2.58e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.32e-06	2.57e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—TPH2—attention deficit hyperactivity disorder	4.32e-06	2.57e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	4.32e-06	2.57e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.32e-06	2.57e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.3e-06	2.56e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.3e-06	2.56e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.29e-06	2.56e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.29e-06	2.56e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—DPYD—attention deficit hyperactivity disorder	4.25e-06	2.53e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.25e-06	2.53e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.25e-06	2.53e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.24e-06	2.52e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.24e-06	2.52e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.23e-06	2.52e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.22e-06	2.52e-05	CbGpPWpGaD
Olanzapine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.19e-06	2.49e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.17e-06	2.48e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.17e-06	2.48e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.16e-06	2.48e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.14e-06	2.47e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.1e-06	2.44e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.09e-06	2.44e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.09e-06	2.44e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	4.08e-06	2.43e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.08e-06	2.43e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.06e-06	2.42e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	4.06e-06	2.42e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.02e-06	2.4e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.01e-06	2.39e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4e-06	2.38e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.99e-06	2.38e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.96e-06	2.36e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.95e-06	2.35e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.95e-06	2.35e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.95e-06	2.35e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.94e-06	2.35e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.94e-06	2.35e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.9e-06	2.32e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.89e-06	2.32e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.89e-06	2.32e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.88e-06	2.31e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	3.88e-06	2.31e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.88e-06	2.31e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.88e-06	2.31e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.86e-06	2.3e-05	CbGpPWpGaD
Olanzapine—HTR6—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.86e-06	2.3e-05	CbGpPWpGaD
Olanzapine—HTR7—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.86e-06	2.3e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.84e-06	2.29e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.83e-06	2.28e-05	CbGpPWpGaD
Olanzapine—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.83e-06	2.28e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.83e-06	2.28e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.82e-06	2.28e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	3.82e-06	2.27e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.82e-06	2.27e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.81e-06	2.27e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.8e-06	2.26e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.8e-06	2.26e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	3.79e-06	2.26e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.79e-06	2.26e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.78e-06	2.25e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.77e-06	2.25e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.76e-06	2.24e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.76e-06	2.24e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.75e-06	2.23e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.75e-06	2.23e-05	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.75e-06	2.23e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	3.73e-06	2.22e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.71e-06	2.21e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.7e-06	2.21e-05	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.69e-06	2.2e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.66e-06	2.18e-05	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.64e-06	2.17e-05	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	3.62e-06	2.15e-05	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	3.59e-06	2.14e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.57e-06	2.13e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	3.57e-06	2.13e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.55e-06	2.11e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.54e-06	2.11e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	3.54e-06	2.11e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.54e-06	2.11e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.52e-06	2.1e-05	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.52e-06	2.1e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.52e-06	2.1e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	3.51e-06	2.09e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	3.51e-06	2.09e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.51e-06	2.09e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.49e-06	2.08e-05	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.49e-06	2.08e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	3.48e-06	2.07e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.46e-06	2.06e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.46e-06	2.06e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.45e-06	2.06e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.45e-06	2.06e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.44e-06	2.05e-05	CbGpPWpGaD
Olanzapine—HRH4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.44e-06	2.05e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.38e-06	2.01e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.32e-06	1.98e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	3.32e-06	1.98e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	3.29e-06	1.96e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.29e-06	1.96e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.28e-06	1.95e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.26e-06	1.94e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.24e-06	1.93e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.21e-06	1.91e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.1e-06	1.85e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.03e-06	1.8e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	3.02e-06	1.8e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.02e-06	1.8e-05	CbGpPWpGaD
Olanzapine—HTR1E—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.99e-06	1.78e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	2.97e-06	1.77e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.96e-06	1.76e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.95e-06	1.76e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.88e-06	1.72e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.86e-06	1.7e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.85e-06	1.7e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.84e-06	1.69e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.83e-06	1.68e-05	CbGpPWpGaD
Olanzapine—ALB—Hemostasis—EP300—attention deficit hyperactivity disorder	2.77e-06	1.65e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.76e-06	1.65e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.76e-06	1.65e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.72e-06	1.62e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.72e-06	1.62e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.69e-06	1.6e-05	CbGpPWpGaD
Olanzapine—HRH2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.67e-06	1.59e-05	CbGpPWpGaD
Olanzapine—DRD5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.65e-06	1.58e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—COMT—attention deficit hyperactivity disorder	2.62e-06	1.56e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—MAOA—attention deficit hyperactivity disorder	2.6e-06	1.55e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.52e-06	1.5e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.51e-06	1.49e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.46e-06	1.47e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.45e-06	1.46e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.45e-06	1.46e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.42e-06	1.44e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.42e-06	1.44e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.42e-06	1.44e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	2.35e-06	1.4e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	2.33e-06	1.39e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	2.33e-06	1.39e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.33e-06	1.39e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.3e-06	1.37e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	2.3e-06	1.37e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	2.29e-06	1.37e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	2.28e-06	1.36e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.26e-06	1.35e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.25e-06	1.34e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	2.16e-06	1.29e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	2.15e-06	1.28e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	2.14e-06	1.28e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.13e-06	1.27e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	2.13e-06	1.27e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.06e-06	1.23e-05	CbGpPWpGaD
Olanzapine—HTR6—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.04e-06	1.22e-05	CbGpPWpGaD
Olanzapine—HTR7—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.04e-06	1.22e-05	CbGpPWpGaD
Olanzapine—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.03e-06	1.21e-05	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.99e-06	1.18e-05	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.96e-06	1.16e-05	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.93e-06	1.15e-05	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.87e-06	1.11e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.86e-06	1.11e-05	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.85e-06	1.1e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	1.83e-06	1.09e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	1.82e-06	1.08e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.78e-06	1.06e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.76e-06	1.05e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.76e-06	1.05e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	1.75e-06	1.04e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.74e-06	1.03e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.57e-06	9.34e-06	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	1.55e-06	9.24e-06	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.51e-06	9.02e-06	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.51e-06	8.97e-06	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.46e-06	8.73e-06	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.44e-06	8.59e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	1.42e-06	8.48e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	1.41e-06	8.42e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	1.4e-06	8.36e-06	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.33e-06	7.92e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.31e-06	7.79e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.3e-06	7.77e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.3e-06	7.75e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.3e-06	7.72e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.28e-06	7.65e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.28e-06	7.63e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.19e-06	7.09e-06	CbGpPWpGaD
Olanzapine—ALB—Metabolism—EP300—attention deficit hyperactivity disorder	1.12e-06	6.69e-06	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	1.01e-06	6.01e-06	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	9.84e-07	5.86e-06	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	9.27e-07	5.52e-06	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	9.19e-07	5.48e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	7.85e-07	4.68e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	6.06e-07	3.61e-06	CbGpPWpGaD
